• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    iBio Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events, Financial Statements and Exhibits

    7/17/26 4:08:53 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IBIO alert in real time by email
    iBio, Inc._July 17, 2026
    0001420720false00014207202026-07-172026-07-17

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (date of earliest event reported): July 17, 2026

    iBio, Inc.

    (Exact name of registrant as specified in charter)

    Delaware

    (State or other jurisdiction of incorporation)

    ​

    ​

    001-35023

    26-2797813

    (Commission File Number)

    (IRS Employer Identification No.)

    ​

    11750 Sorrento Valley Road, Suite 200

    San Diego, California 92121

    (Address of principal executive offices and zip code)

    (979) 446-0027

    (Registrant’s telephone number including area code)

    N/A

    (Former Name and Former Address)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

    ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

    ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

    IBIO

    The Nasdaq Stock Market LLC

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☐

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

    ​

    ​

    ​

    ​

    Item 5.08. Shareholder Director Nominations.

     

    To the extent applicable, the information in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.

    ​

    Item 8.01. Other Events.

    iBio, Inc. (the “Company”) currently plans to hold its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) on October 14, 2026. The Company intends to set the record date for determining the stockholders of record who will be entitled to vote at the 2026 Annual Meeting as the close of business on September 1, 2026. The time and location of the 2026 Annual Meeting will be as set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting to be filed with the Securities and Exchange Commission.

    Because the scheduled date of the 2026 Annual Meeting is more than 30 days prior to the anniversary of the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”), prior disclosed deadlines regarding the submission of stockholder proposals pursuant to Rule 14a-8 (“Rule 14a-8”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for the 2026 Annual Meeting are no longer applicable. The Company is hereby providing notice of certain revised deadlines for the submission of stockholder proposals in connection with the 2026 Annual Meeting. In order for a stockholder proposal, submitted pursuant to Rule 14a-8, to be considered timely for inclusion in the Company’s proxy statement and form of proxy for the 2026 Annual Meeting, such proposal must be received by the Company by August 1, 2026. The Company has determined that August 1, 2026 is a reasonable time before the Company plans to begin printing and mailing its proxy materials. Therefore, in order for a stockholder to submit a proposal for inclusion in the Company’s proxy materials for the 2026 Annual Meeting, the stockholder must comply with the requirements set forth in Rule 14a-8, including with respect to the subject matter of the proposal, and must deliver the proposal and all required documentation to the Company no later than August 1, 2026. The public announcement of an adjournment or postponement of the date of the 2026 Annual Meeting will not commence a new time period (or extend any time period) for submitting a proposal pursuant to Rule 14a-8.

    Pursuant to the Company’s Second Amended and Restated Bylaws, because the scheduled date of the 2026 Annual Meeting is more than 20 days prior to the anniversary of the 2025 Annual Meeting, prior disclosed deadlines regarding the timely submission of stockholder proposals that any stockholder intends to present at the 2026 Annual Meeting but does not seek to have included in the proxy materials pursuant to Rule 14a-8, are no longer applicable. To be considered timely, such stockholder proposals must be received by the Company at its principal executive office no later than July 27, 2026, which is the tenth day following public disclosure of the date of the 2026 Annual Meeting via this Current Report on Form 8-K. Such stockholder proposals must include the information required by the Company’s Second Amended and Restated Bylaws with respect to each stockholder making the proposal or nomination and each proposal or nomination that such stockholder intends to present at the 2026 Annual Meeting.

    In addition, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than August 15, 2026, which is 60 days prior to the date of the 2026 Annual Meeting.

    ​

    Item 9.01.     Financial Statements and Exhibits.

    (d)    Exhibits.

    ​

    ​

    ​

    Exhibit No.

      ​ ​ ​

    Description

    104

    ​

    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

    ​

    ​

    ​

    -1-

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

     

    IBIO, INC.

     

     

    Date: July 17, 2026

    By: 

    /s/ Marc Banjak

     

     

    Name:

    Marc Banjak

    ​

    ​

    Title:

    Chief Legal Officer

    ​

    ​

    ​

    -2-

    Get the next $IBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IBIO

    DatePrice TargetRatingAnalyst
    6/8/2026$5.00Outperform
    Raymond James
    6/5/2026$6.00Buy
    B. Riley Securities
    10/21/2025$5.00Outperform
    Oppenheimer
    10/17/2025$2.00Outperform
    Leerink Partners
    5/28/2024$5.00Buy
    Chardan Capital Markets
    11/29/2021$1.50Mkt Outperform
    JMP Securities
    11/29/2021$1.50Outperform
    JMP Securities
    More analyst ratings

    $IBIO
    SEC Filings

    View All

    iBio Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events, Financial Statements and Exhibits

    8-K - iBio, Inc. (0001420720) (Filer)

    7/17/26 4:08:53 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - iBio, Inc. (0001420720) (Filer)

    7/1/26 7:33:29 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by iBio Inc.

    10-Q - iBio, Inc. (0001420720) (Filer)

    5/12/26 4:18:59 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

    Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone Full dataset to be presented at European Association for the Study of Diabetes (EASD) Annual Meeting SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced new preclinical data from its obese non-human primate (NHP) study evaluatin

    7/1/26 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio to Participate in Upcoming Healthcare Investor Conferences

    SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference. Jefferies Global Healthcare ConferencePresentation Date: Thursday, June 4, 2026Time: 11:40 a.m. ETLocation: Marriott Marquis, New York A livestream of the event can be accessed link, and a replay of the presenta

    6/2/26 4:01:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

    IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with obesity SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innovator developing therapies for cardiometabolic and cardiopulmonary diseases and obesity, today announced the dosing of the first participant in its Phase 1 clinical trial of IBIO-600, the Company's most advanced obesity and cardiometabolic asset and its first program to enter human clinical dev

    6/2/26 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:34:37 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Brenner Martin bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 101% to 18,316 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:34:02 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Banjak Marc bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 490% to 11,066 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:33:31 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Stoner Elizabeth

    4 - iBio, Inc. (0001420720) (Issuer)

    5/19/26 7:44:29 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Stoner Elizabeth

    3 - iBio, Inc. (0001420720) (Issuer)

    5/15/26 7:00:13 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Banjak Marc

    4 - iBio, Inc. (0001420720) (Issuer)

    3/27/26 4:05:18 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on iBio with a new price target

    Raymond James initiated coverage of iBio with a rating of Outperform and set a new price target of $5.00

    6/8/26 9:02:58 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on iBio with a new price target

    B. Riley Securities initiated coverage of iBio with a rating of Buy and set a new price target of $6.00

    6/5/26 8:13:34 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on iBio with a new price target

    Oppenheimer initiated coverage of iBio with a rating of Outperform and set a new price target of $5.00

    10/21/25 7:20:34 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Leadership Updates

    Live Leadership Updates

    View All

    iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

    SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment of Elizabeth Stoner, M.D., M.S. to its Board of Directors. Dr. Stoner is appointed as an independent member of the Board of Directors and as a member of the Compensation Committee, following the transition of Eef Schimmelpennink from this position, who has stepped down from the Board. "We are excited to welcome Liz to our Board of Directors at a pivotal moment in iBio's evolution as clinical-staged company," said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Of

    5/8/26 7:15:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio to Begin Trading on the Nasdaq Stock Exchange

    SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol "IBIO." The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented, "We are pleased to announce our listing on the Nas

    2/19/25 4:05:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Strengthens Board with Appointment of Two New Independent Directors

    SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. "These appointments expand and strengthen our board to align with iBio's vision of becoming a next-generation antibody discovery and development company with a robust clinical pipeline of therapeutic antibodies for cardiometabolic diseases and oncology. As a seasoned CFO, David brings extensive financial experience and industry relationships that will benefit iBio as we

    11/25/24 8:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Financials

    Live finance-specific insights

    View All

    iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

    SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio's strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and will include a presentation from Martin Brenner, DVM, Ph.D., iBio's Chief Executive Officer and Chief Scientific Officer, and Cory Schwartz, Ph.D., the Company's Director of Research and Early Development. iBio is engineering a selective bispecific antibo

    3/16/26 4:30:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

    Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of next-generation antibody therapies, today announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake

    6/24/25 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

    Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.Martin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibo

    6/23/25 4:15:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by iBio Inc.

    SC 13G - iBio, Inc. (0001420720) (Subject)

    11/14/24 8:47:49 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by iBio Inc.

    SC 13G/A - iBio, Inc. (0001420720) (Subject)

    11/14/24 4:48:52 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by iBio Inc. (Amendment)

    SC 13G/A - iBio, Inc. (0001420720) (Subject)

    4/9/24 5:22:43 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care